Adlai Nortye ANL
NASDAQ ANL
$15.01 +0.26 (+1.76%)
At close: Sep 4, 2026 · 4:00 PM EDT

Adlai Nortye (ANL) Cash & Equivalents (2022 - 2026)

Adlai Nortye (ANL) posted quarterly Cash & Equivalents of $8.1 million for Q4 2025, down 86.77% year-over-year from $60.9 million in Q4 2024, and down 81.75% quarter-over-quarter from $44.1 million in Q2 2025.

Analysis

Adlai Nortye (ANL) Cash & Equivalents (2022 - 2026) Analysis & Trends

Adlai Nortye (ANL) has reported Cash & Equivalents for 4 consecutive years, with $8.1 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Cash & Equivalents fell 86.77% year-over-year to $8.1 million; the TTM figure through Dec 2025 stood at $8.1 million (down 86.77% YoY), while the FY2025 annual figure was $8.1 million, down 86.77% from the prior year.
  • Cash & Equivalents fell to $8.1 million in Q4 2025 per ANL's latest filing, from $44.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $98.0 million in Q2 2024 and bottomed at $8.1 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $57.6 million across 4 years, with a median of $52.5 million in 2024.
  • Annual changes were most pronounced in 2023 — Cash & Equivalents surged 113.98% — and 2025, when it plunged 86.77%.
  • Adlai Nortye's Cash & Equivalents stood at $42.8 million in 2022, then jumped by 113.98% to $91.5 million in 2023, then plunged by 33.43% to $60.9 million in 2024, then slumped by 86.77% to $8.1 million in 2025.
  • Business Quant data shows ANL's Cash & Equivalents at $8.1 million in Q4 2025, $44.1 million in Q2 2025, and $60.9 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.14 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 2.46 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 3.58 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 1.72 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 815.44 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 5.10 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 1.71 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 811.99 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 544.80 Mn
10 Adlai Nortye 500.08 Mn 268.19 Mn - 132.59 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 132.59 Mn
Dec 31, 2025 8.06 Mn
Jun 30, 2025 44.14 Mn
Dec 31, 2024 60.90 Mn
Jun 30, 2024 97.98 Mn
Dec 31, 2023 91.49 Mn
Dec 31, 2022 42.76 Mn